Fibroblasts as architects of cancer pathogenesis  by Marsh, Timothy et al.
Biochimica et Biophysica Acta 1832 (2013) 1070–1078
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
Fibroblasts as architects of cancer pathogenesis☆
Timothy Marsh a, Kristian Pietras b, Sandra S. McAllister a,c,d,e,⁎
a Hematology Division, Brigham & Women's Hospital, Boston, MA 02115, USA
b Department of Laboratory Medicine, Lund University Cancer Center, Lund, Sweden
c Department of Medicine, Harvard Medical School Boston, MA 02115, USA
d Harvard Stem Cell Institute, Boston, MA 02115, USA
e Broad Institute of Harvard and MIT, Boston, MA 02115, USA☆ This article is part of a Special Issue entitled: Fibrosi
to human disease.
⁎ Corresponding author at: Harvard Medical School, B
Blackfan Circle, Karp 5-214, Boston, MA 02115, USA. Te
617 355 9093.
E-mail address: smcallister1@partners.org (S.S. McA
0925-4439/$ – see front matter © 2012 Published by El
http://dx.doi.org/10.1016/j.bbadis.2012.10.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 September 2012
Received in revised form 16 October 2012
Accepted 19 October 2012
Available online 30 October 2012
Keywords:
Fibrosis
Cancer
Cancer-associated ﬁbroblasts
Bone marrow cells
HeterogeneityStudies of epithelial cancers (i.e., carcinomas) traditionally focused on transformation of the epithelium (i.e., the
cancer cells) and how aberrant signaling within the cancer cells modulates the surrounding tissue of origin. In
more recent decades, the normal cells, blood vessels, molecules, and extracellular components that surround
the tumor cells, collectively known as the “tumor microenvironment” or “stroma”, have received increasing
attention and are now thought to be key regulators of tumor initiation and progression. Of particular relevance
to thework reviewedherein are theﬁbroblasts,whichmake up themajor cell typewithin themicroenvironment
ofmost carcinomas. Due to their inherent heterogeneity, plasticity, and function, it is perhaps not surprising that
ﬁbroblasts are ideal modulators of normal and cancerous epithelium; however, these aspects also present chal-
lenges if we are to interrupt their tumor-supportive functions. Here, we review the current body of knowledge
and the many questions that still remain about the special entity known as the cancer-associated ﬁbroblast.
This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2012 Published by Elsevier B.V.1. Introduction
1.1. Form and function — normal, activated, and
cancer-associated ﬁbroblasts
Fibroblasts are derived from the primitivemesenchyme, have an elon-
gated, spindle-like morphology, and are metabolically active (the sufﬁx
“blast” typically denotes an active metabolism). As the most abundant
cells of the connective tissue in animals, ﬁbroblasts both synthesize and
degrade extracellular matrix (ECM) components by expressing collagens,
ﬁbronectins, laminins, elastins, proteoglycans, integrins, matrix met-
alloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs),
and a host of other ECM proteins that are expressed in a tissue-speciﬁc
manner (reviewed in [1,2]). Consequently, ﬁbroblasts are responsible
for providing structural integrity to most tissues. Fibroblasts also produce
the tissue-speciﬁc basementmembrane that provides a protective barrier
around the specialized epithelium, thereby contributing to speciﬁcity, po-
larity, and functionality of the epithelium [2]. There is also evidence indi-
cating that ﬁbroblasts communicate through the basement membrane to
alter epithelial homeostasis, proliferation, and differentiation [3].s: Translation of basic research
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llister).
sevier B.V.Fibroblast activity is crucial during processes ofwound healing and in-
ﬂammation. When tissue damage occurs, resident ﬁbroblast populations
proliferate and invade the injured area in response to platelet clotting.
Platelets adhere to exposed subendothelium at sites of vessel injury and
release their bioactive cargo (e.g., TGFβ1, PDGF, IL1-B,MMPs, TIMPs), pre-
dominantly from α-granules that degrade the basement membrane, in-
duce cell proliferation and migration, and recruit inﬂammatory cells and
ﬁbroblasts (reviewed in [4]). Under such conditions,ﬁbroblasts are gener-
ally considered to be “activated”. In particular, as the healing process pro-
gresses,ﬁbroblasts turn on expression of aﬁlamentous actin, alpa-smooth
muscle actin (αSMA), which enables them to exert contractile forces to
close the wound. Local tissue contractility is mediated by focal adhesions
between the activated ﬁbroblasts – at this point called myoﬁbroblasts –
and the ECM. Moreover, contractile ﬁbroblasts are known to regulate in-
terstitial ﬂuid volume and pressure via cytoskeletal infrastructure [5].
After wound closure, the balance of MMPs and TIMPs secreted by ﬁbro-
blasts is changed to favor ECM degradation (as opposed to synthesis)
which leads tomassive apoptosis of themyoﬁbroblast population. Conse-
quently, only quiescent, non-contractile ﬁbroblasts are left at the resolved
wound site, and as such, myoﬁbroblasts are only observed under patho-
logical conditions.
The wound healing process seems to be co-opted by tumors;
indeed, tumors have been likened to “wounds that never heal” [6].
However, unlike wound resolution in which ﬁbroblasts “de-activate”,
the myoﬁbroblast population persists during ﬁbrosis or tumorigene-
sis for reasons that are not clear. It seems that normal ﬁbroblasts
have a bimodal effect on cancerous cells in that early in tumorigenesis,
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vances, ﬁbroblasts are subverted to promote tumor growth — these
tumor-supportive ﬁbroblasts are referred to as cancer-associated ﬁbro-
blasts (CAFs). In some cases, normal ﬁbroblasts suppress malignant con-
version of immortalized prostate epithelium [7], whereas in the breast,
normalﬁbroblasts can induce the transition of already transformedductal
carcinoma in situ to invasive carcinoma [8]. The oncogenic transformation
of the epithelium may subvert normal ﬁbroblasts and potentiate their
ability to promote tumor growth. Concordantly, one study has shown
that suppression of the retinoblastoma (Rb) protein in pancreatic epithe-
lium induces a selection pressure for ﬁbroblasts that lack p53 and subse-
quently results in p53-inactivated epithelium [9]. Although the reasons
why CAFs remain perpetually activated remain to be elucidated, it is
very clear that ﬁbroblasts participate in an elaborate, reciprocal cross-
talk with the cancerous epithelium.
2. Cancer-associated ﬁbroblasts — heterogeneity or a spectrum
of phenotypes?
It is widely accepted that CAFs are a heterogeneous cell type and
that this diversity may arise from their cell (s) of origin, the tissue
in which they develop, or their activation state at any given time.
This heterogeneity has presented challenges to precisely and exclu-
sively identifying CAFs and to distinguishing them from other cell
types that express similar markers upon histopathological analysis
of tumors and tissues (Fig. 1). Instead, CAFs are more readily distin-
guished from their normal counterparts by their phenotype, prolifer-
ation rate, and differential expression of ECM constituents [10].
CAFs aremost oftendenotedby expressionofαSMA. Several addition-
almarkers are used to identify CAFs, including: vimentin, platelet-derived
growth factor receptor alpha (PDGFR-α), platelet-derived growth factor
receptor beta (PDGFR-β), ﬁbroblast speciﬁc protein (FSP-1), and ﬁbro-
blast activation protein (FAP) [11–14]. Nevertheless, no one marker
speciﬁcally labels all CAFs or clearly distinguishes CAFs fromnormalﬁbro-
blasts or other closely-related cell types. These other cell types include
pericytes (cells that line blood vessels, also known asmural cells), smooth
muscle cells, epithelial cells that have undergone an epithelial-to-
mesenchymal transition (EMT), myoepithelial cells (speciﬁcally in
the breast), and some adipocytes (Fig. 1). Most often, in order to
generally classify these various cell types, a combination of markers
must be used. For example, αSMA-positive CAFs can be distinguished
from pericytes, which stain positively for neuron glial antigen 2 (NG2)
and regulator of G-protein signaling 5 (RGS5). RGS5 has been shown
to be overexpressed in abnormal tumor vasculature and colocalizes pre-
dominantly with PECAM-1/CD31 and less so with PDGFR-α and αSMA
[15]. Although some carcinoma cells express FSP-1, FSP-1-positive ﬁ-
broblast sub-populations present in the tumor microenvironment
have been shown to facilitate malignant progression. For example, in a
syngeneic mouse model of melanoma, PDGF-CC signaling recruited ﬁ-
broblasts with differential expression of FSP-1, PDGFR-α and αSMA
[11]. Additionally, vimentin is expressed in most mesenchymal cell
types as well as epithelial cells that have undergone an epithelial-to-
mesenchymal transition (EMT). Due to the apparent heterogeneity of
ﬁbroblasts and their diverse origins, it has therefore been difﬁcult to
distinguish true ﬁbroblasts from ﬁbroblast-like cells. Moreover, identify-
ingmarkers to labelﬁbroblast sub-populations that exclusively contribute
to cancer progression in various organs has presented challenges (Fig. 1).
Molecular proﬁling studies have also revealed the heterogeneity
of ﬁbroblast and CAF populations, yet have also suggested that core
signatures, at least among sup-populations of ﬁbroblasts, might pre-
dict tumor-supportive function. For example, gene expression analy-
sis of ﬁbroblasts isolated from breast cancer patient tumors yielded
subtype-speciﬁc molecular signatures, especially with respect to expres-
sion of genes encoding cytoskeletal and integrin signaling proteins [16].
On the other hand, a study inwhichﬁbroblastswere isolated from tendif-
ferent anatomical regions and exposed to serum (mimicking a woundresponse), revealed a common transcriptional signature, termed the ﬁ-
broblast core serum response (CSR), that was also identiﬁed in CAFs iso-
lated from various carcinomas and predicted metastatic progression in
patients with breast, lung, and gastric cancers [16]. Similarly, differences
in tumor-promoting abilitywere found between normal tissueﬁbroblasts
and CAFs when examined for their prostaglandin (PGE2) secretory phe-
notype, which is elevated in tumors [17]. Two recent studies deﬁned
very similar CAF expression proﬁles that represented pro-
inﬂammatory signatures also found in CAFs derived from cancer pa-
tients. In one study using a K14-HPV16 mouse model of multistep
squamous skin carcinogenesis, this signature included: Cox2, IL-1β,
OPN, IL-6, CXCL1/2 [18]. In the other study using a xenograft
model of breast cancer progression, enhanced expression of many
of these same proteins were found in CAFs relative to normal mam-
mary ﬁbroblasts [19]. Importantly, this second study also identiﬁed
the molecular modulator that caused ﬁbroblasts to adopt this
pro-tumorigenic CAF signature — the secreted growth factor, granulin
(GRN) [19]. Hence, common biological responses of ﬁbroblasts to their
microenvironmental cues (e.g., serum exposure) might reveal how ﬁ-
broblasts acquire their CAF phenotypes. However, these responses
seem restricted to different subpopulations of ﬁbroblasts. Given this di-
versity of biological functions and their obvious heterogeneity, markers
and methods to identify different CAF populations for therapeutic pur-
poses, while challenging, would seem of utmost importance.
3. Fibroblasts in cancer pathophysiology
It has long been thought that ﬁbroblast behavior is dictated by the ep-
ithelium, but recentlymore attention has been paid to the possibility that
ﬁbroblasts actively drive tumorigenesis and cancer progression
[8–11,20,21]. There is now evidence to suggest that ﬁbroblasts play im-
portant roles during the entire course of tumor development, from the
pre-neoplastic state until the terminal stage of cancer progression —
metastasis.
3.1. Cancer initiation — do ﬁbroblasts direct tumorigenesis?
Tumor initiation is typically conceptualized as the accumulation of
genetic and epigenetic mutations in the epithelium that results in re-
cruitment of a reactive stroma.While the role of ﬁbroblasts in de novo
transformation or induction of carcinoma from epithelium lacking
oncogenic mutation is currently debated, some studies have shown
that ﬁbroblasts facilitate carcinoma formation from epithelium that
is cancer-prone.
Studies of prostate cancer have demonstrated that isolated CAFs,
but not normal ﬁbroblasts, can induce the transformation of immor-
talized epithelial cells [20,22]. Transgenic mouse models have provid-
ed some insights into CAF-derived factors that are responsible for
tumor initiation. For example, Wnt1 overexpression in ﬁbroblasts
transformsmammary epithelial cells from C57BL/6mice [23]. Additional-
ly, overexpression ofHGF and/or TGFβ inﬁbroblastswas demonstrated to
be sufﬁcient for inducing ductal carcinoma in situ (DCIS), adenocarcino-
ma, and poorly differentiated tumors in the breast [24]. Knockoutmodels
and depletion experiments have also demonstrated the importance of ﬁ-
broblast activation in tumorigenesis. One study using FSP-1-deﬁcient
mice showed reduced tumor growth and attenuatedmetastatic potential
of an otherwise highly metastatic murine mammary carcinoma cell-line,
whereas injection of wild type ﬁbroblasts partially rescued this effect
[25]. Furthermore, knockout of TGFβRII in FSP-1-positive cells promoted
prostate neoplasia and forestomach squamous cell carcinoma [10].
A recent study using mice containing conditional alleles of Pten
and an Fsp-cre transgene, showed that inactivation of PTEN speciﬁcal-
ly in mammary ﬁbroblasts signiﬁcantly increased the incidence and
rate of progression to adenocarcinoma of MMTV-ErbB2/Neu-driven
tumors [21]. Upon examination of the pre-neoplastic mammary
glands of the mice in this study, signiﬁcant increases in ECM
Fig. 1. Histological images of sections from human tissue surgical specimens that were immunohistochemically stained with some markers commonly used to identify
cancer-associated ﬁbroblasts: alpha-smooth muscle actin (αSMA), ﬁbroblast-speciﬁc protein-1 (FSP-1), vimentin (VIM), platelet-derived growth factor receptor beta (PDGFR-β);
and pericytes: neuron glial antigen 2 (NG2). As discussed herein, no one marker speciﬁcally labels all CAFs or clearly distinguishes CAFs from normal ﬁbroblasts or other closely
related cell types. For example, αSMA not only denotes cancer-associated ﬁbroblasts (CAFs), but also myoepithelial cells (ME), pericytes (PC), and smooth muscle cells (SMC) in
both normal and cancer tissues. Shown is normal breast tissue is from a female, age 23 (with the exception of the vimentin stain, which is from a 45 year old woman); normal
prostate tissue is from a 51 year old man; cancerous breast and prostate tumor tissues are from a 40 year old woman with ductal carcinoma and a 64 year old man with high
grade adenocarcinoma, respectively. Positive staining for indicated proteins appears brown. Tissue sections were counterstained with hematoxylin (blue) to indicate cell nuclei
and extracellular material. Scale bar=100 μm. Images were adapted and used with permission from The Human Protein Atlas (www.proteinatlas.org) and only protein stainings
with annotated expression ranked as high reliability are displayed.
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the PTEN-speciﬁc gene signature of the pre-neoplastic ﬁbroblasts
from these mice was remarkably similar to stromal signatures found
in patients with breast cancer. However, as mentioned earlier, FSP-1
marks both normal and activated ﬁbroblasts, as well as some epithe-
lial cells, in the mammary gland [26], so it is not clear that the accel-
erated growth was due exclusively to the PTEN-null ﬁbroblasts.
Finally, a number of studies have implicated reactive stroma, in-
cluding activated ﬁbroblasts, in accelerating the appearance ofcarcinoma (reviewed in [27]). Many of these studies incorporate the
use of irradiated ﬁbroblasts with pre-transformed epithelium that
bear mutations in tumor suppressor genes. The most recent example
comes from a study in which Trp53-deﬁcient mammary epithelilum
was transplanted into irradiated hosts (whole body irradiation) that
had previously undergone mammary fat pad clearance [28]. In this
study, estrogen receptor-negative tumors developed with increased in-
cidence and at an accelerated pace above controls. Another type of reac-
tive ﬁbroblast, the senescent ﬁbroblast, has also been implicated in
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study using amodel of skin carcinogenesis elegantly showed that senes-
cent ﬁbroblasts drove progression of pre-neoplastic epithelium in an
osteopontin-dependent manner [29].
3.2. Early stage cancer — ﬁbroblasts pave the way for cancer
There is clear evidence that CAFs play an important role during the
early stages of tumorigenesis. As tumors progress, the architecture of
the host tissue becomes highly distorted with aberrant accumulation
of ECM components. One hallmark of this process within the tumor
microenvironment is collagen cross-linking. Hints about the molecu-
lar basis of this come from experimental models showing that CAFs
are a major source of lysyl-oxidase (LOX), which cross-links collagen,
and that inhibiting LOX delays the onset of breast cancer [30]. In fact,
LOX activity has been observed in many types of aggressively growing
cancers [30]. Likewise, in breast and colon cancer models, CAFs ex-
press uPA and uPAR, which modulate ECM degradation, which, in
turn, increases the bioavailability of growth factors that are typically
sequestered by the ECM [31].
In addition to modulating ECM components, CAFs are known to reg-
ulate proliferation of the epithelium. In some cases, enhanced prolifera-
tion is the result of direct paracrine interactions between tumor cells
and CAFs, and in others, it appears to be an indirect effect of inﬂammato-
ry processes in which CAFs serve as mediators (discussed in more detail
later). Under various contexts, CAFs produce a repertoire of growth fac-
tors and cytokines that inﬂuence the behavior of the epithelium, includ-
ing HGF, EGF, IGFs, IGFBPs, b-FGF, and TGFβ, to name a few (reviewed in
[20]). In other contexts, inﬂammatory processes that impinge upon ﬁbro-
blasts endow themwith the ability to directly affect tumor cell behavior.
For example, generation of reactive oxygen species (ROS) in the inﬂam-
matory microenvironment has been shown to modulate CAF
transdifferentiation, thereby enhancing their tumor-promoting func-
tions [32,33]. Interestingly, it has also been shown that induction of
autophagy in the CAF compartment helps to promote tumor cell survival
via processes involving downregulation of caveolin-1 and the subsequent
stabilization of hypoxia-inducible factor-1 alpha (HIF1-α) [34].
3.3. CAFs in cancer progression and metastasis
Metastasis, which is the leading cause of death in patients with
solid tumors, is a highly inefﬁcient process, and it is estimated that
less than 1% of disseminated tumor cells are able to form viable me-
tastases. Not surprisingly, successful metastatic progression also in-
volves ﬁbroblasts. Within the primary tumor site, it has been shown
that factors secreted by CAFs, including TGFβ-1, induce tumor cells
to undergo EMT, thereby promoting tumor cell motility, invasion,
and metastasis [35,36]. Likewise, knockout of one allele of TGFβRII
in FSP-1-positive cells yielded more metastases in the MMTV-PyMT
mammary tumor model [37]. Underscoring these results, transgenic
mice deﬁcient in FSP-1 cells did not incur metastases when engrafted
with a highly metastatic murine mammary carcinoma cells [25]. As
primary modulators of the ECM, as mentioned earlier, CAFs certainly
help tumor cells to invade the surrounding tissue by forming the in-
vasive front [38]. Indeed, it was demonstrated that CAF expression
of caveolin-1 leads to matrix remodeling, invasiveness, and increased
metastases in mice injected with breast adenocarcinoma cells [39].
Fibroblasts likely play a role at metastatic sites as well, as activated
ﬁbroblasts have been observed at metastatic sites where they pro-
mote tumor cell proliferation [40] . Fibroblast production of periostin
at the site of a micrometastasis was shown to be crucial for metastatic
colonization and maintenance of cancer stem cell-like properties,
which are thought to be necessary for initiation of a new tumor [41].
Other studies have shown that systemic signaling cascades that operate
as a consequence to the body's response to cancer, aid construction of
the tumor-supportive microenvironment, including CAFs, at metastaticsites [19,42]. Such studies have raised important questions that have yet
to be fully elucidated, such as: what is the source of CAFs found in met-
astatic sites? Do disseminated tumor cells have to “start all over again”
to build their specialized CAF compartment? One early study suggested
the interesting possibility that tumor cells take their stroma, including
CAFs, with them [43]. The stromal requirements of micrometastases is
a rate limiting step in the colonization of secondary organs and fully elu-
cidating the mechanisms by which normal stromal compartments of
the secondary organ prevent or promote metastatic growth is crucial
to developing therapies against this life threatening condition.
4. Tracing the origins of CAFs
Perhaps one of the most asked questions in the study of tumor mi-
croenvironment is: what is the source of cancer-associated ﬁbro-
blasts? It is likely that CAFs are derived from a variety of sources.
The origin of myoﬁbroblasts in ﬁbrosis has been extensively studied
and has provided insight, both technically and conceptually, into the
sourceof CAFs in cancer. Currently, there are three prevailinghypotheses
regarding the source of activated ﬁbroblasts in tumors. The ﬁrst, and
most commonly studied, is that CAFs derive from resident cells that are
recruited from local sources into the tumor microenvironment by the
malignant epithelium. These resident cells might include normal tissue
ﬁbroblasts (as discussed in detail above), and tissue mesenchymal
stem cells (MSCs). Second, circulating ﬁbrocyte progenitors and bone
marrow-derived cells have been demonstrated to extravasate into the tis-
sue where the tumor resides and differentiate into cells with ﬁbroblast-
like phenotypes. A third and ﬁnal scenario is that other cell types, such
as pericytes, myoepithelial cells, and endothelial cells transdifferentiate
to give rise to the tumor ﬁbroblast-like population.
4.1. Calling upon resident ﬁbroblasts
As discussed at length earlier, several lines of evidence suggest
that activation of resident ﬁbroblast populations give rise to CAFs.
Studies of the origin of ﬁbroblasts during wound healing and organ ﬁ-
brosis have helped shed light on how this process occurs in cancer. As
stated earlier, the tumor and ﬁbrotic microenvironment is a key reg-
ulator of pathological progression. Resident ﬁbroblasts surrounding
the malignancy are commonly thought to be the ﬁrst responders to
the site of insult that the tumor provides.
Although not well understood, resident mesenchymal stem/
progenitor cells (MSCs) have been shown to contribute to tumor
growth in various model systems [44], suggesting that these cells,
which share a lineage relationshipwithﬁbroblasts,might provide a source
of CAFs. MSCs have been shown to differentiate into myoﬁbroblast-like
cells (marked by αSMA and collagen 1) [45] and to secrete tumor-
promoting factors, including VEGF, IL-8, HGF and IGF-1 [46]. It is not
clear whether resident MSCs differentiate into CAFs for several rea-
sons. First, techniques to isolate MSCs that can differentiate into the
various lineages from resident tissue is challenging and it is not clear
which cell-surface markers would clearly and exclusively distinguish
MSCs, if possible. Second, once MSCs are brought into cell culture,
they are highly susceptible to differentiation and selection pressures.
4.2. Bone marrow and circulating cells as CAF reservoirs
As vasculature in tumors is highly permeable, the inﬂux of circu-
lating cells increases and the relative contribution of bone marrow-
derived cells to the tumor stroma also increases. The contribution of
bone marrow-derived cells to the CAF population is debated and ap-
pears to be context-dependent. In a study of inﬂammation-induced
gastric cancer, up to 20% of the αSMA+ in the tumor stroma were
shown to be derived from bone marrow mesenchymal progenitor
cells [47]. Yet studies of pancreatic and other cancers demonstrated
that bone marrow-derived cells contribute a small percentage of the
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formed with a highly reactive, myoﬁbroblast-rich stroma, demon-
strated that none of the αSMA+ population was of bone marrow or-
igin [19]. However, interesting studies in patients who had previously
received a bone marrow transplant from a donor of the opposite sex
indicated that some tissue ﬁbroblasts were of donor origin [50,51].
Bone marrow-derived MSCs have been of interest due to their
ability to home to sites of inﬂammation, tissue repair, and neoplasia
in experimental models [52–54]. Other studies have identiﬁed some
of the growth factors and cytokines that attract MSCs to tumor sites
(e.g., VEGF, EGF, HGF, b-FGF, PDGF, CCL2) [55–57]. In studies using
an ovarian cancer cell-line, Skov3, admixed with human MSCs, the
resulting tumor microenvironment harbored abundant cells with
both CAF and pericyte-like phenotypes [57]; however, this study did
not determine whether the CAFs arose from the implanted MSCs or
from recruitment of other host cells that gave rise to the CAF popula-
tion. Bone marrow-derived MSCs have also been shown to play an
important role in tumor progression [58]. Nevertheless, whether or
not MSCs should be equated with CAFs is not yet clear.
Circulating ﬁbrocytes have also been considered as a source of CAFs,
as they have been shown to be recruited to injured tissues [59,60] and
to contribute to the αSMA myoﬁbroblasts observed in a mouse model
of allergic asthma [61]. Furthermore, in a model of bleomycin-induced
lung ﬁbrosis, GFP bone marrow chimera mice have elevated levels of
GFP+, collagen 1 producing ﬁbroblasts in the lungs [62]. Fibrocytes
are thought to be of bone marrow origin due to their expression of leu-
kocyte marker CD45, bonemarrow stem cell antigen CD34, CD11b, and
ﬁbroblastic markers such as vimentin, collagen I/III and ﬁbronection
(reviewed in [63]). As ﬁbrocytes can lose CD45 and CD34 markers
when in circulation, it is likely that the cumulative effects of ﬁbrocytes
in tissue ﬁbrosis and cancer are unrecognized.
4.3. Transdifferentiation of resident tissue cells
The plasticity of various epithelial and mesenchymal cell types
during pathological processes has become a topic of intense investi-
gation. A number of cell types found in the tumor microenvironment
or in proximal tissue have been proposed as candidates for the CAF
compartment. These cells include: pericytes, adipocytes, endothelial
cells, and even the epithelial cancer cells.
Pericytes, which inherently expressαSMA, have been of particular in-
terest as a speculated source ofﬁbroblasts in recent studies,mainly due to
their reported functions in other pathological conditions. One study uti-
lized lineage tracing of pericytes/perivascular cells to demonstrate their
transdifferentiaton into interstitial, proliferative myoﬁbroblast-like cells
in kidney ﬁbrosis [64]. Additionally, ADAM12+ perivascular cells in ﬁ-
brotic regions have been shown to undergo a progressive differentiation
program into myoﬁbroblasts [65]. Furthermore, pericytes have been
shown to contribute to scar formation in spinal cord injury [66]. Pericytes
are known to detach from tumor vasculature, thereby contributing to the
inherent “leakiness” of tumor vasculature [67] [68], leading to the idea
that these pericytes, should they remain viable in the tumor microenvi-
ronment,might give rise to cellswith a CAF-like phenotype. Nevertheless,
whether or not pericytes contribute in amajorway to the CAF population
remains to be determined conclusively.
Given theirmesenchymal lineage relationshipwithﬁbroblasts, tissue
adipocytes have been proposed as a likely source of CAFs. For example,
in a breast cancer model, local adipose tissue contributed ~29% of the
αSMA-positive population and comprised ~27% of the NG2-positive
cells [69]. Moreover, adipose precursor cells have been shown to induce
expression of ﬁbronectin,αSMA, and vimentin in 4T1murinemammary
carcinoma cells, consistent with tumor-associated ﬁbroblastic cells [70].
Finally, one study demonstrated that breast tumor-derived TNF-α and
IL-11 prevented differentiation of adipocyte precursors, causing them
to expand as a ﬁbroblastic population to contribute to the desmoplastic
stroma [71]. Nevertheless, direct proof that mature adipocytes de-differentiate within the tumormicroenvironment (e.g., in themammary
gland) to give rise to the CAF population has not been provided as of yet.
One lineage tracing experiment in amodel of kidney ﬁbrosis demon-
strated that endothelial cells acquire ﬁbroblast markers during a pro-
cesses coined “EndMT” — endothelial to mesenchymal transition [72].
In this context, endothelial cells underwent a partial transdifferentiation
to acquire ﬁbroblastic markers αSMA, FSP-1, vimentin, and N-cadherin,
while retaining endothelial markers VE-Cadherin, CD31, Tie1, and Tie2
(reviewed in [73]). A related study showed that up to 40% of CAFs
arise as a consequence of EndMT in two differentmurine cancer models
[74].
Perhaps themost accepted transdifferentiation program occurs dur-
ing embryonic development when epithelial cells transition into mes-
enchymal cells, in a process termed the epithelial-to-mesenchymal
transition (EMT). The existence of a permanent and irreversible EMT
in adult tissue is often debated. Recently, the EMT has been classiﬁed
into three functionally different processes that occur in distinct biolog-
ical settings [35]. Type 1which occurs during implantation, embryogen-
esis, and organ development is well studied and will not be discussed
here (reviewed in [35,75]). Type 2 occurs during tissue regeneration
and ﬁbrosis (discussed by other authors in this special issue). Type 3,
discussed below, is associated with tumor progression and metastasis.
As discussed earlier, in general, the cancer research community views
EMT as a process by which cancerous epithelial cells undergo a partial,
and possibly reversible, transition to a mesenchymal-like state for
the puposes of invasion and metastasis. Epithelial cells that undergo
EMT in vitro are marked by acquisition of mesenchymal markers
(e.g.,αSMA, FSP-1, vimentin, desmin, andN-cadherin) and loss of epithe-
lial markers (e.g., E-cadherin), while for the most part, retaining expres-
sion of epithelial-speciﬁc cytokeratins (reviewed in [75]). It has been
suggested that epithelial cells undergo an EMT after exposure to oxida-
tive stress induced my MMPs to become myoﬁbroblasts [76]. The EMT
phenotype therefore supports functions that are not normal to terminal-
ly differentiated epithelial cells, such as anchorage-independent survival,
loss of homotypic cell-cell contact, cell motility, invasion, and ability to
breach the basement membrane (reviewed in [35,77,78]), several prop-
erties that are characteristics of ﬁbroblast-like cells. Indeed, an epithelial
cell-line derived from a breast cancer biopsy displayed ﬁbroblast charac-
teristics and had the ability to differentiate into myoﬁbroblasts [79].
Cancer cells that have undergone EMT are typically found at the invasive
front of tumors in variousmodel systems, further supporting their role in
themetastatic process. At this point, while it is generally thought that the
EMT is important for cancer progression, it is still debated whether cells
that have undergone an EMT ﬁll the role of CAFs.
The underlying heterogeneity of CAFs and the promiscuity of
markers that are used to identify them (Fig. 1) also present challenges
to identifying their origins. Additional studies using transgenic
models and in vivo lineage-tracing techniques that incorporate pre-
cise, well-accepted, cell-speciﬁc promoters might help us ﬁnd more
answers to the questions about the origins of CAFs.
5. Interactions in the tumor microenvironment
Crosstalk within the tumor microenvironment is not limited to
paracrine signaling between CAFs and malignant cells, but also occurs
between different resident and distant stromal cell types. CAFs active-
ly engage these multiple other stromal cell types, including endothe-
lial cells, bone marrow-derived cells (BMDCs) and inﬂammatory cells,
in order to stimulate cancer growth, angiogenesis and metastatic
spread.
5.1. CAFs and endothelial cells
Cancer-associated ﬁbroblasts participate in processes supporting
tumor growth, angiogenesis and progression through multiple and
principally differentmechanisms involving crosstalk with other cellular
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have been highlighted as providers of a multitude of pro-angiogenic
cues (growth factors, proteases, extra-cellular matrix constituents, cel-
lular recruitment) in various tumor types. The stimulation of angio-
genesis afforded by stromal ﬁbroblasts is in line with their primary
localization at the leading edge of tumors, where there is a manifested
demand for an expanded vascular supply [38,80]. CAFs secrete and
deposit numerous growth factors in the tumor microenvironment that
stimulate endothelial cell growth and angiogenesis. Studies using mice
genetically engineered with a reporter for vascular endothelial growth
factor (VEGF)-A have demonstrated dramatic induction of VEGF-A
transcription in the stroma of both spontaneously arising, as well as
implanted tumors [81]. Indeed, stromal cells in ovarian carcinomas pro-
vide most angiogenic growth factors in higher quantities than do the
overt malignant cells [82]. Provision of angiopoietin-1 and -2 by CAFs
acts to stabilize the neo-vasculature of ovarian carcinomas [83], indicat-
ing that ﬁbroblasts in this context also stimulate vessel patency.
While neo-angiogenesis is typically initiated by the hypoxic tumor
microenvironment, CAFs are also in many cases induced to secrete
pro-angiogenic factors in response to paracrine signaling events. Produc-
tion of various isoforms of the platelet-derived growth factor (PDGF)
family by malignant cells serves to recruit and activate pro-angiogenic
CAFs in various cancers [84]. Hence, paracrine PDGF stimulation of
CAFs induces production of the prototypical pro-angiogenic inducer ﬁ-
broblast growth factor (FGF)-2 in both cervical carcinomas andmelano-
ma [11,85].
Interestingly, CAFs activated by PDGF-CC in melanomas also secrete
the extracellular matrix protein osteopontin, the action of which is
known to synergistically stimulate angiogenesis together with FGF-2
and promote autocrine VEGF-A signaling in endothelial cells [11,86–88].
Consistent with the role of PDGFs as essential upstreammediators of an-
giogenic cues provided by CAFs, malignant cells genetically deﬁcient for
VEGF-A make up for this lack by paracrine activation of PDGFR-α in
CAFs, thus stimulating production of stromal VEGF-A [89,90]. Moreover,
autocrine stimulation of CAFs by the cytokine CXCL14 in prostate cancers
also results in induction of FGF-2 and subsequent neo-angiogenesis [91].
Finally, CAFs indirectly regulate the process of angiogenesis through
abundant provision of extracellular matrix (ECM) products, such as
collagen (s), osteopontin and tenascin-C, as well as by secreting matrix-
remodeling proteases, including members of the matrix metallo-
proteinase (MMP) and the a disintegrin and metallo-proteinase
(ADAM) families [92]. Paradoxically, excessive production of ECM
and a prolonged ﬁbrotic reaction is detrimental to the angiogenic pro-
cess, most likely by physically restricting endothelial sprout formation
and tip cell migration, and attenuation of the desmoplastic response
in pancreatic adenocarincomas through inhibition of hedgehog signal-
ing alleviates the angiogenic blockade and improves tumor perfusion
[93,94]. Taken together, our current knowledge points towards a pivotal
role for stromal ﬁbroblasts in releasing tumors from dormancy through
activation of the angiogenic switch, and identiﬁes CAF-endothelial cell
crosstalk as a hitherto unexploited target for cancer therapy.
5.2. CAFs and bone marrow-derived cells
In addition to supporting tumor growth through orchestration of
paracrine signaling networks within the tumor parenchyma, CAFs medi-
ate long distance effects throughmobilization of various BMDCs. Striking-
ly, CAFs, but not normal ﬁbroblasts, secrete stromal cell-derived factor
(SDF)-1 in order to recruit Sca1+CD31+ BMDCs that act as endothelial
progenitors and incorporate into the neo-vasculature [95]. In this study,
SDF-1 was speciﬁcally expressed by αSMA-positive myoﬁbroblasts.
In addition to CAFs affecting BMDCs, BMDCs can affect the CAF
phenotype. Interestingly, recruitment of a distinct set of Sca1+c-Kit-
hematopoietic BMDCs induces myoﬁbroblast differentiation and
expression of αSMA through secretion of granulin (GRN) [19]. The
mature myoﬁbroblast component subsequently promotes multipleaspects of tumor growth, angiogenesis and progression systemical-
ly through production of an array of cytokines and growth factors,
including CXCL1, CXCL2, IL1A and B, IL6 and IL8 [19]. Thus, recipro-
cal signaling between CAFs and BMDCs represents a conceptually
novel and viable cancer drug target, e.g., through targeting of SDF-1 or
GRN.
5.3. CAFs and immune modulation
It is increasingly appreciated that phenotypic modulation of the im-
mune response is a feature of most, if not all, cancers [96]. CAFs manip-
ulate the inﬂammatory microenvironment through two principally
distinct mechanisms. Firstly, CAFs harbor a pro-inﬂammatory expres-
sion proﬁle that serves to recruit macrophages, neutrophils and other
stimulatory immune cells that promote various aspects of tumor pro-
gression [19,97,98]. Notably, CAF-derived S100A4 mediates tumor
inﬁltration of T-cells, the action of which promotes lung metastatic
formation in experimental breast cancers [99].
Secondly, immune editing by CAF-derived factors act to suppress
tumor detection and rejection by the host immune system [100]. In
this context, stromal ﬁbroblasts frommelanoma, but not from normal
skin, impede NK cell cytotoxicity both through cell-to-cell contacts
and through release of PGE2 [101]. In addition, stromal cells express-
ing FAP orchestrate an immuno-suppressive tumor microenviron-
ment in pancreatic adenocarcinomas [102]. In accordance with their
role as modulators of the immune response in tumors, depletion of
CAFs from experimental breast cancers – via DNA vaccination against
FAP – results in suppression of metastatic spread through shifting the
polarization of the immunemicroenvironment from Th2 to Th1 [103].
6. The CAF as a clinical entity
Given the importance of stromal support in carcinogenesis and
tumor progression, CAFs are thought to provide an important target
for therapeutic strategies to improve outcomes for cancer patients.
In the normal breast, ﬁbroblasts are quite abundant and, in the case
of carcinogenesis, inﬁltration of CAFs and their ECM is the reason
why breast cancer often presents as a palpable lump. Additionally,
high mammographic density is associated with an increased risk of
developing breast cancer [104]. Recent clinical and translational stud-
ies have made it clear that the extent of stromal desmoplasia is linked
to prognosis and that molecular proﬁling of stromal markers is pre-
dictive of outcome [105,106]. In the clinic, a myoﬁbroblast-rich, reac-
tive stroma is almost always found in human adenocarcinomas and is
associated with invasiveness and poor prognosis [20,107].
Understanding the heterogeneity within ﬁbroblast populations
will be important if we are to effectively target the tumor promoting
functions of these cells. Indeed, ﬁbroblasts express differential levels
of key interleukins and chemokines in breast cancers of different sub-
types (i.e., basal-like and luminal-like) [108]. An interesting recent
study provided a plausible explanation for why triple negative breast
cancer (ER−/PR−/HER2−; TNBC) is more prevalent among African
American women than Caucasian women by showing that normal
mammary ﬁbroblasts from African American women support the
growth of TNBC cells while those from Caucasian women did not
[109]. As TNBC denotes poor prognosis and there are no targeted ther-
apies against this kind of tumor, studies aiming to elucidatewhy certain
ﬁbroblasts promote one kind of disease or another are crucial.
Unfortunately, however, there are no current therapies deisgned
to directly inhibit or eliminate tumor-promoting CAFs. Currently, an
ongoing clinical trial is investigating the effect of irradiation of the
area around non-invasive or early invasive breast cancer (http://
www.clinicaltrials.gov). This trial is based on pre-clinical data that
support the role of the microenvironment in progression and invasion
of breast cancer; however, in some pre-clinical models irradiation of
themammary gland actually promotes transformation of immortalized
1076 T. Marsh et al. / Biochimica et Biophysica Acta 1832 (2013) 1070–1078tumor cells [110]. A separate study on pancreatic tumors suggested that
blocking HGF signaling in addition to irradiation of the stromamay help
prevent invasion of cancerous epithelial cells [111].
Perhaps indirect targeting of other components in the tumor micro-
environment will serve to inhibit CAF accumulation or function. For ex-
ample, certain tyrosine kinase inhibitors that target signaling pathways
(e.g., VEGFR, PDGFR) that are active in stromal cell populations (e.g. en-
dothelial cells and ﬁbroblasts) have been proposed. In the past decades,
there has been much interest in the engineering of anti-angiogenesis
molecules that prevent the angiogenic switch in early malignancies
and thereby prevent tumor growth. Unfortunately, these efforts have
been met with disappointment, as patients often acquire resistance to
drugs like Avastin (VEGFA antibody), which has recently been removed
as an FDA-approved therapy for breast cancer [112]. Studies show that
cancer cells can evolve resistance to blockade of the VEGF pathway;
however, concomitant inhibition of FGF and VEGF during this process
results in tumor stasis and a reduction in tumor burden [113]. Con-
versely, results from pre-clinical models have led to suggestions that
enhancing tumor vascularization (e.g., inhibiton of PDGF-B or hedge-
hog) might help improve delivery of chemotherapy, thereby attenuat-
ing tumor progression [94,114].
Targeting the structure and homeostasis of the abundant ECM found
within tumors may one day prove useful in therapeutic approaches as
well. For example, lysyl oxidase enzymes, responsible for collagen cross-
linking, are elevated in many cancers [115]; however, the ECM turnover
in these conditions is abnormal. Although strategies to inhibitMMP activ-
ity have been proposed [116], clinical trials usingMMP inhibitors yielded
disappointing results due to serious toxicity and lack of speciﬁcity [117].
Finally, targeting factors that promote and sustain the CAF pheno-
type, as demonstrated in pre-clinical models, might lead to novel ther-
apeutic approaches. For example, targeting BMDC-derived granulin,
which was shown to induce the tumor-promoting function of normal
mammary ﬁbroblasts, might provide a means to prevent CAF support
of cancer progression [19]. Autocrine factors, such as TGFb and SDF-1,
that drive and sustain CAF populationsmight provide a basis for explor-
ingways to inhibit the tumor support network [118]. Likewise, elucidat-
ing some of the currently unknown factors derived from cancer cells
that promote CAF function [18,119] should also lead to identiﬁcation
of therapeutic candidates.
7. Perspectives
The aims of many pre-clinical cancer research efforts have been
to elucidate mechanisms by which certain tumors progress toward
life-threatening malignancy and acquire resistance to treatments. As
such, many studies consider the variety of cell types that comprise a
solid tumor. In that vein, if targeted therapies are to be successful,
then one must take into account not only the molecular target of a
given therapy, but also the patient population that is most likely to re-
spond to that therapy. Also, delineating pathways that provide tu-
mors with adaptive resistance to current therapies allows for the
opportunity to attack tumors via multiple modalities. It is likely that
understanding similarities between cancer pathogenesis, ﬁbrosis,
and wound healing will be a step in that direction. Deﬁning CAFs, un-
derstanding their behavior, and elucidating how they arise are one
part of this challenging task and hold the promise of designing ways
to attack tumor-supportive CAFs, perhaps while sparing normal ﬁbro-
blasts that promote homeostasis.
Acknowledgements
We thank Dr. Brian Bierie for helpful discussion. KP is the Göran
and Birgitta Grosskopf Professor of Molecular Medicine at Lund Uni-
versity, and is supported by a Linnaeus grant to the STARGET consor-
tium and by the ERC Starting Grant TUMORGAN. SSM is supported bythe Harvard Stem Cell Institute, the Brigham Research Institute, and
NIH NCI RO1 CA166284-01.
References
[1] M. Jacob, L. Chang, E. Pure, Fibroblast activation protein in remodeling tissues,
Current Molecular Medicine (2012) (Epub ahead of print).
[2] R. Kalluri, Basement membranes: structure, assembly and role in tumour angio-
genesis, Nat. Rev. Cancer 3 (2003) 422–433.
[3] L. Ronnov-Jessen, O.W. Petersen, M.J. Bissell, Cellular changes involved in conver-
sion of normal to malignant breast: importance of the stromal reaction, Physiol.
Rev. 76 (1996) 69–125.
[4] A.T. Nurden, Platelets, inﬂammation and tissue regeneration, Thromb. Haemost.
105 (Suppl. 1) (2011) S13–S33.
[5] H. Wiig, K. Rubin, R.K. Reed, New and active role of the interstitium in control of
interstitial ﬂuid pressure: potential therapeutic consequences, Acta Anaesthesiol.
Scand. 47 (2003) 111–121.
[6] H.F. Dvorak, Tumors: wounds that do not heal. Similarities between tumor stro-
ma generation and wound healing, N. Engl. J. Med. 315 (1986) 1650–1659.
[7] A.F. Olumi, G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, G.R. Cunha,
Carcinoma-associated ﬁbroblasts direct tumor progression of initiated human
prostatic epithelium, Cancer Res. 59 (1999) 5002–5011.
[8] M. Hu, J. Yao, D.K. Carroll, S. Weremowicz, H. Chen, D. Carrasco, A. Richardson, S.
Violette, T. Nikolskaya, Y. Nikolsky, E.L. Bauerlein, W.C. Hahn, R.S. Gelman, C.
Allred, M.J. Bissell, S. Schnitt, K. Polyak, Regulation of in situ to invasive breast
carcinoma transition, Cancer Cell 13 (2008) 394–406.
[9] R. Hill, Y. Song, R.D. Cardiff, T. Van Dyke, Selective evolution of stromal mesen-
chyme with p53 loss in response to epithelial tumorigenesis, Cell 123 (2005)
1001–1011.
[10] N.A. Bhowmick, A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K.
Washington, E.G. Neilson, H.L. Moses, TGF-beta signaling in ﬁbroblasts modu-
lates the oncogenic potential of adjacent epithelia, Science 303 (2004) 848–851.
[11] C. Anderberg, H. Li, L. Fredriksson, J. Andrae, C. Betsholtz, X. Li, U. Eriksson, K.
Pietras, Paracrine signaling by platelet-derived growth factor-CC promotes
tumor growth by recruitment of cancer-associated ﬁbroblasts, Cancer Res. 69
(2009) 369–378.
[12] P. Micke, A. Ostman, Tumour-stroma interaction: cancer-associated ﬁbroblasts
as novel targets in anti-cancer therapy? Lung Cancer 45 (Suppl. 2) (2004)
S163–S175.
[13] H. Sugimoto, T.M. Mundel, M.W. Kieran, R. Kalluri, Identiﬁcation of ﬁbroblast het-
erogeneity in the tumormicroenvironment, Cancer Biol. Ther. 5 (2006) 1640–1646.
[14] J. Paulsson, T. Sjoblom, P. Micke, F. Ponten, G. Landberg, C.H. Heldin, J. Bergh, D.J.
Brennan, K. Jirstrom, A. Ostman, Prognostic signiﬁcance of stromal platelet-derived
growth factor beta-receptor expression in human breast cancer, Am. J. Pathol. 175
(2009) 334–341.
[15] A. Silini, C. Ghilardi, S. Figini, F. Sangalli, R. Fruscio, R. Dahse, R.B. Pedley, R.
Giavazzi, M. Bani, Regulator of G-protein signaling 5 (RGS5) protein: a novel
marker of cancer vasculature elicited and sustained by the tumor's proangiogenic
microenvironment, Cell. Mol. Life Sci. 69 (2012) 1167–1178.
[16] J. Tchou, A.V. Kossenkov, L. Chang, C. Satija, M. Herlyn, L.C. Showe, E. Pure,
Human breast cancer associated ﬁbroblasts exhibit subtype speciﬁc gene ex-
pression proﬁles, BMC Med. Genet. 5 (2012) 39.
[17] J.A. Rudnick, L.M. Arendt, I. Klebba, J.W. Hinds, V. Iyer, P.B. Gupta, S.P. Naber, C.
Kuperwasser, Functional heterogeneity of breast ﬁbroblasts is deﬁned by a pros-
taglandin secretory phenotype that promotes expansion of cancer-stem like
cells, PLoS One 6 (2011) e24605.
[18] N. Erez, M. Truitt, P. Olson, S.T. Arron, D. Hanahan, Cancer-associated ﬁbroblasts
are activated in incipient neoplasia to orchestrate tumor-promoting inﬂamma-
tion in an NF-kappaB-dependent manner, Cancer Cell 17 (2010) 135–147.
[19] M. Elkabets, A.M. Gifford, C. Scheel, B. Nilsson, F. Reinhardt, M.A. Bray, A.E.
Carpenter, K. Jirstrom, K. Magnusson, B.L. Ebert, F. Ponten, R.A. Weinberg, S.S.
McAllister, Human tumors instigate granulin-expressing hematopoietic cells
that promote malignancy by activating stromal ﬁbroblasts in mice, J. Clin. Invest.
121 (2011) 784–799.
[20] R. Kalluri, M. Zeisberg, Fibroblasts in cancer, Nat. Rev. Cancer 6 (2006) 392–401.
[21] A.J. Trimboli, C.Z. Cantemir-Stone, F. Li, J.A. Wallace, A. Merchant, N. Creasap, J.C.
Thompson, E. Caserta, H. Wang, J.L. Chong, S. Naidu, G. Wei, S.M. Sharma, J.A.
Stephens, S.A. Fernandez, M.N. Gurcan, M.B. Weinstein, S.H. Barsky, L. Yee, T.J.
Rosol, P.C. Stromberg, M.L. Robinson, F. Pepin, M. Hallett, M. Park, M.C.
Ostrowski, G. Leone, Pten in stromal ﬁbroblasts suppresses mammary epithelial
tumours, Nature 461 (2009) 1084–1091.
[22] S.W. Hayward, Y. Wang, M. Cao, Y.K. Hom, B. Zhang, G.D. Grossfeld, D.
Sudilovsky, G.R. Cunha, Malignant transformation in a nontumorigenic human
prostatic epithelial cell line, Cancer Res. 61 (2001) 8135–8142.
[23] S.F. Jue, R.S. Bradley, J.A. Rudnicki, H.E. Varmus, A.M. Brown, The mouse Wnt-1
gene can act via a paracrine mechanism in transformation of mammary epithe-
lial cells, Mol. Cell. Biol. 12 (1992) 321–328.
[24] C. Kuperwasser, T. Chavarria, M.Wu, G.Magrane, J.W. Gray, L. Carey, A. Richardson,
R.A.Weinberg, Reconstruction of functionally normal andmalignant human breast
tissues in mice, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4966–4971.
[25] B. Grum-Schwensen, J. Klingelhofer, C.H. Berg, C. El-Naaman, M. Grigorian, E.
Lukanidin, N. Ambartsumian, Suppression of tumor development andmetastasis for-
mation in mice lacking the S100A4 (mts1) gene, Cancer Res. 65 (2005) 3772–3780.
[26] R. Kalluri, E.G. Neilson, Epithelial–mesenchymal transition and its implications
for ﬁbrosis, J. Clin. Invest. 112 (2003) 1776–1784.
1077T. Marsh et al. / Biochimica et Biophysica Acta 1832 (2013) 1070–1078[27] M.A. Cichon, A.C. Degnim, D.W. Visscher, D.C. Radisky, Microenvironmental in-
ﬂuences that drive progression from benign breast disease to invasive breast
cancer, J. Mammary Gland Biol. Neoplasia 15 (2010) 389–397.
[28] D.H. Nguyen, H.A. Oketch-Rabah, I. Illa-Bochaca, F.C. Geyer, J.S. Reis-Filho, J.H.
Mao, S.A. Ravani, J. Zavadil, A.D. Borowsky, D.J. Jerry, K.A. Dunphy, J.H. Seo, S.
Haslam, D. Medina, M.H. Barcellos-Hoff, Radiation acts on the microenviron-
ment to affect breast carcinogenesis by distinct mechanisms that decrease can-
cer latency and affect tumor type, Cancer Cell 19 (2011) 640–651.
[29] E. Pazolli, X. Luo, S. Brehm, K. Carbery, J.J. Chung, J.L. Prior, J. Doherty, S. Demehri,
L. Salavaggione, D. Piwnica-Worms, S.A. Stewart, Senescent stromal-derived
osteopontin promotes preneoplastic cell growth, Cancer Res. 69 (2009)
1230–1239.
[30] K.R. Levental, H. Yu, L. Kass, J.N. Lakins, M. Egeblad, J.T. Erler, S.F. Fong, K. Csiszar,
A. Giaccia, W. Weninger, M. Yamauchi, D.L. Gasser, V.M. Weaver, Matrix
crosslinking forces tumor progression by enhancing integrin signaling, Cell
139 (2009) 891–906.
[31] F. Blasi, N. Sidenius, The urokinase receptor: focused cell surface proteolysis, cell
adhesion and signaling, FEBS Lett. 584 (2010) 1923–1930.
[32] B. Cat, D. Stuhlmann, H. Steinbrenner, L. Alili, O. Holtkotter, H. Sies, P. Brenneisen,
Enhancement of tumor invasion depends on transdifferentiation of skin ﬁbroblasts
mediated by reactive oxygen species, J. Cell Sci. 119 (2006) 2727–2738.
[33] A. Toullec, D. Gerald, G. Despouy, B. Bourachot, M. Cardon, S. Lefort, M. Richardson,
G. Rigaill,M.C. Parrini, C. Lucchesi, D. Bellanger,M.H. Stern, T. Dubois, X. Sastre-Garau,
O. Delattre, A. Vincent-Salomon, F. Mechta-Grigoriou, Oxidative stress promotes
myoﬁbroblast differentiation and tumour spreading, EMBO Mol. Med. 2 (2010)
211–230.
[34] U.E. Martinez-Outschoorn, C. Trimmer, Z. Lin, D. Whitaker-Menezes, B. Chiavarina,
J. Zhou, C. Wang, S. Pavlides, M.P. Martinez-Cantarin, F. Capozza, A.K. Witkiewicz,
N. Flomenberg, A. Howell, R.G. Pestell, J. Caro, M.P. Lisanti, F. Sotgia, Autophagy
in cancer associated ﬁbroblasts promotes tumor cell survival: role of hypoxia,
HIF1 induction and NFkappaB activation in the tumor stromal microenvironment,
Cell Cycle 9 (2010) 3515–3533.
[35] R. Kalluri, R.A. Weinberg, The basics of epithelial–mesenchymal transition,
J. Clin. Invest. 119 (2009) 1420–1428.
[36] S.A. Mani, W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F.
Reinhard, C.C. Zhang, M. Shipitsin, L.L. Campbell, K. Polyak, C. Brisken, J. Yang,
R.A. Weinberg, The epithelial–mesenchymal transition generates cells with
properties of stem cells, Cell 133 (2008) 704–715.
[37] W.B. Fang, I. Jokar, A. Chytil, H.L. Moses, T. Abel, N. Cheng, Loss of one Tgfbr2 al-
lele in ﬁbroblasts promotes metastasis in MMTV: polyoma middle T transgenic
and transplant mouse models of mammary tumor progression, Clin. Exp. Metas-
tasis 28 (2011) 351–366.
[38] C. Gaggioli, S. Hooper, C. Hidalgo-Carcedo, R. Grosse, J.F. Marshall, K.
Harrington, E. Sahai, Fibroblast-led collective invasion of carcinoma cells with
differing roles for RhoGTPases in leading and following cells, Nat. Cell Biol. 9
(2007) 1392–1400.
[39] J.G. Goetz, S. Minguet, I. Navarro-Lerida, J.J. Lazcano, R. Samaniego, E. Calvo, M.
Tello, T. Osteso-Ibanez, T. Pellinen, A. Echarri, A. Cerezo, A.J. Klein-Szanto, R.
Garcia, P.J. Keely, P. Sanchez-Mateos, E. Cukierman, M.A. Del Pozo, Biomechani-
cal remodeling of the microenvironment by stromal caveolin-1 favors tumor in-
vasion and metastasis, Cell 146 (2011) 148–163.
[40] E. Olaso, C. Salado, E. Egilegor, V. Gutierrez, A. Santisteban, P. Sancho-Bru, S.L.
Friedman, F. Vidal-Vanaclocha, Proangiogenic role of tumor-activated hepatic
stellate cells in experimental melanoma metastasis, Hepatology 37 (2003)
674–685.
[41] I. Malanchi, A. Santamaria-Martinez, E. Susanto, H. Peng, H.A. Lehr, J.F. Delaloye,
J. Huelsken, Interactions between cancer stem cells and their niche govern met-
astatic colonization, Nature 481 (2012) 85–89.
[42] H.S. Kuznetsov, T. Marsh, B.A. Markens, Z. Castano, A. Greene-Colozzi, S.A. Hay,
V.E. Brown, A.L. Richardson, S. Signoretti, E.M. Battinelli, S.S. McAllister, Identiﬁca-
tion of luminal breast cancers that establish a tumor supportivemacroenvironment
deﬁned by pro-angiogenic platelets and bonemarrow derived cells, Cancer Discov.
(2012) (Epub ahead of print).
[43] D.G. Duda, A.M. Duyverman, M. Kohno, M. Snuderl, E.J. Steller, D. Fukumura, R.K.
Jain, Malignant cells facilitate lung metastasis by bringing their own soil, Proc.
Natl. Acad. Sci. U. S. A. 107 (2010) 21677–21682.
[44] M. Zhao, P.C. Sachs, X. Wang, C.I. Dumur, M.O. Idowu, V. Robila, M.P. Francis, J.
Ware, M. Beckman, A. Rizki, S.E. Holt, L.W. Elmore, Mesenchymal stem cells in
mammary adipose tissue stimulate progression of breast cancer resembling
the basal-type, Cancer Biol. Ther. 13 (2012).
[45] N. Walker, L. Badri, S. Wettlaufer, A. Flint, U. Sajjan, P.H. Krebsbach, V.G.
Keshamouni, M. Peters-Golden, V.N. Lama, Resident tissue-speciﬁc mesenchymal
progenitor cells contribute to ﬁbrogenesis in human lung allografts, Am. J. Pathol.
178 (2011) 2461–2469.
[46] M. Razmkhah, M. Jaberipour, A. Hosseini, A. Safaei, B. Khalatbari, A. Ghaderi,
Expression proﬁle of IL-8 and growth factors in breast cancer cells and
adipose-derived stem cells (ASCs) isolated from breast carcinoma, Cell.
Immunol. 265 (2010) 80–85.
[47] M. Quante, S.P. Tu, H. Tomita, T. Gonda, S.S. Wang, S. Takashi, G.H. Baik, W.
Shibata, B. Diprete, K.S. Betz, R. Friedman, A. Varro, B. Tycko, T.C. Wang, Bone
marrow-derived myoﬁbroblasts contribute to the mesenchymal stem cell
niche and promote tumor growth, Cancer Cell 19 (2011) 257–272.
[48] G. Ishii, T. Sangai, T. Oda, Y. Aoyagi, T. Hasebe, N. Kanomata, Y. Endoh, C.
Okumura, Y. Okuhara, J. Magae, M. Emura, T. Ochiya, A. Ochiai, Bone-marrow-
derived myoﬁbroblasts contribute to the cancer-induced stromal reaction,
Biochem. Biophys. Res. Commun. 309 (2003) 232–240.[49] G. Ishii, T. Sangai, T. Ito, T. Hasebe, Y. Endoh, H. Sasaki, K. Harigaya, A. Ochiai, In
vivo and in vitro characterization of human ﬁbroblasts recruited selectively into
human cancer stroma, Int. J. Cancer 117 (2005) 212–220.
[50] N.C. Direkze, K. Hodivala-Dilke, R. Jeffery, T. Hunt, R. Poulsom, D. Oukrif, M.R. Alison,
N.A. Wright, Bone marrow contribution to tumor-associated myoﬁbroblasts and ﬁ-
broblasts, Cancer Res. 64 (2004) 8492–8495.
[51] N.C. Direkze, M.R. Alison, Bone marrow and tumour stroma: an intimate rela-
tionship, Hematol. Oncol. 24 (2006) 189–195.
[52] B. Hall, M. Andreeff, F. Marini, The participation of mesenchymal stem cells in
tumor stroma formation and their application as targeted-gene delivery vehi-
cles, Handb. Exp. Pharmacol. (2007) 263–283.
[53] S.C. Hung, W.P. Deng, W.K. Yang, R.S. Liu, C.C. Lee, T.C. Su, R.J. Lin, D.M. Yang, C.W.
Chang,W.H. Chen, H.J. Wei, J.G. Gelovani, Mesenchymal stem cell targeting ofmicro-
scopic tumors and tumor stroma development monitored by noninvasive in vivo
positron emission tomography imaging, Clin. Cancer Res. 11 (2005) 7749–7756.
[54] S. Kidd, E. Spaeth, J.L. Dembinski, M. Dietrich, K. Watson, A. Klopp, V.L. Battula,
M. Weil, M. Andreeff, F.C. Marini, Direct evidence of mesenchymal stem cell tro-
pism for tumor and wounding microenvironments using in vivo bioluminescent
imaging, Stem Cells 27 (2009) 2614–2623.
[55] R.M. Dwyer, S.M. Potter-Beirne, K.A. Harrington, A.J. Lowery, E. Hennessy, J.M.
Murphy, F.P. Barry, T. O'Brien, M.J. Kerin, Monocyte chemotactic protein-1 secreted
by primary breast tumors stimulates migration of mesenchymal stem cells, Clin.
Cancer Res. 13 (2007) 5020–5027.
[56] B. Feng, L. Chen, Review of mesenchymal stem cells and tumors: executioner or
coconspirator? Cancer Biother. Radiopharm. 24 (2009) 717–721.
[57] E.L. Spaeth, J.L. Dembinski, A.K. Sasser, K. Watson, A. Klopp, B. Hall, M. Andreeff,
F. Marini, Mesenchymal stem cell transition to tumor-associated ﬁbroblasts con-
tributes to ﬁbrovascular network expansion and tumor progression, PLoS One 4
(2009) e4992.
[58] A.E. Karnoub, A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, G.W. Bell, A.L.
Richardson, K. Polyak, R. Tubo, R.A. Weinberg, Mesenchymal stem cells within
tumour stroma promote breast cancer metastasis, Nature 449 (2007) 557–563.
[59] R. Abe, S.C. Donnelly, T. Peng, R. Bucala, C.N. Metz, Peripheral blood ﬁbrocytes:
differentiation pathway and migration to wound sites, J. Immunol. 166 (2001)
7556–7562.
[60] R. Bucala, L.A. Spiegel, J. Chesney, M. Hogan, A. Cerami, Circulating ﬁbrocytes deﬁne a
new leukocyte subpopulation that mediates tissue repair, Mol. Med. 1 (1994) 71–81.
[61] M. Schmidt, G. Sun, M.A. Stacey, L. Mori, S. Mattoli, Identiﬁcation of circulating
ﬁbrocytes as precursors of bronchial myoﬁbroblasts in asthma, J. Immunol.
171 (2003) 380–389.
[62] N. Hashimoto, H. Jin, T. Liu, S.W. Chensue, S.H. Phan, Bone marrow-derived pro-
genitor cells in pulmonary ﬁbrosis, J. Clin. Invest. 113 (2004) 243–252.
[63] E.C. Keeley, B. Mehrad, R.M. Strieter, The role of ﬁbrocytes in ﬁbrotic diseases of
the lungs and heart, Fibrogenesis Tissue Repair 4 (2011) 2.
[64] B.D. Humphreys, S.L. Lin, A. Kobayashi, T.E. Hudson, B.T. Nowlin, J.V. Bonventre, M.T.
Valerius, A.P. McMahon, J.S. Dufﬁeld, Fate tracing reveals the pericyte and not epi-
thelial origin of myoﬁbroblasts in kidney ﬁbrosis, Am. J. Pathol. 176 (2010) 85–97.
[65] S. Dulauroy, S.E. Di Carlo, F. Langa, G. Eberl, L. Peduto, Lineage tracing and genetic
ablation of ADAM12(+) perivascular cells identify a major source of proﬁbrotic
cells during acute tissue injury, Nat. Med. (2012) (Epub ahead of print).
[66] C. Goritz, D.O. Dias, N. Tomilin, M. Barbacid, O. Shupliakov, J. Frisen, A pericyte
origin of spinal cord scar tissue, Science 333 (2011) 238–242.
[67] H.Y. Chang, J.B. Sneddon, A.A. Alizadeh, R. Sood, R.B. West, K. Montgomery, J.T.
Chi, M. van de Rijn, D. Botstein, P.O. Brown, Gene expression signature of ﬁbro-
blast serum response predicts human cancer progression: similarities between
tumors and wounds, PLoS Biol. 2 (2004) E7.
[68] D.M. McDonald, P.L. Choyke, Imaging of angiogenesis: frommicroscope to clinic,
Nat. Med. 9 (2003) 713–725.
[69] S. Kidd, E. Spaeth, K. Watson, J. Burks, H. Lu, A. Klopp, M. Andreeff, F.C. Marini, Or-
igins of the tumor microenvironment: quantitative assessment of adipose-derived
and bone marrow-derived stroma, PLoS One 7 (2012) e30563.
[70] E. Devarajan, Y.H. Song, S. Krishnappa, E. Alt, Epithelial-mesenchymal transition
in breast cancer lines is mediated through PDGF-D released by tissue-resident
stem cells, Int. J. Cancer 131 (2012) 1023–1031.
[71] L. Meng, J. Zhou, H. Sasano, T. Suzuki, K.M. Zeitoun, S.E. Bulun, Tumor necrosis
factor alpha and interleukin 11 secreted by malignant breast epithelial cells in-
hibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer
binding protein alpha and peroxisome proliferator-activated receptor gamma:
mechanism of desmoplastic reaction, Cancer Res. 61 (2001) 2250–2255.
[72] E.M. Zeisberg, S.E. Potenta, H. Sugimoto, M. Zeisberg, R. Kalluri, Fibroblasts in
kidney ﬁbrosis emerge via endothelial-to-mesenchymal transition, J. Am. Soc.
Nephrol. 19 (2008) 2282–2287.
[73] D. Medici, R. Kalluri, Endothelial-mesenchymal transition and its contribution to the
emergence of stem cell phenotype, Semin. Cancer Biol. (2012) (Epub ahead of print).
[74] E.M. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, R. Kalluri, Discovery of endothelial
to mesenchymal transition as a source for carcinoma-associated ﬁbroblasts,
Cancer Res. 67 (2007) 10123–10128.
[75] J. Yang, R.A. Weinberg, Epithelial-mesenchymal transition: at the crossroads of
development and tumor metastasis, Dev. Cell 14 (2008) 818–829.
[76] D.C. Radisky, P.A. Kenny, M.J. Bissell, Fibrosis and cancer: do myoﬁbroblasts
come also from epithelial cells via EMT? J. Cell. Biochem. 101 (2007) 830–839.
[77] C.J. Creighton, J.C. Chang, J.M. Rosen, Epithelial–mesenchymal transition (EMT)
in tumor-initiating cells and its clinical implications in breast cancer, J. Mamma-
ry Gland Biol. Neoplasia 15 (2010) 253–260.
[78] Y. Wang, B.P. Zhou, Epithelial–mesenchymal transition in breast cancer progres-
sion and metastasis, Chin. J. Cancer 30 (2011) 603–611.
1078 T. Marsh et al. / Biochimica et Biophysica Acta 1832 (2013) 1070–1078[79] O.W. Petersen, H.L. Nielsen, T. Gudjonsson, R. Villadsen, F. Rank, E. Niebuhr, M.J.
Bissell, L. Ronnov-Jessen, Epithelial to mesenchymal transition in human breast
cancer can provide a nonmalignant stroma, Am. J. Pathol. 162 (2003) 391–402.
[80] D. Granot, Y. Addadi, V. Kalchenko, A. Harmelin, L.A. Kunz-Schughart, M.
Neeman, In vivo imaging of the systemic recruitment of ﬁbroblasts to the angio-
genic rim of ovarian carcinoma tumors, Cancer Res. 67 (2007) 9180–9189.
[81] D. Fukumura, R. Xavier, T. Sugiura, Y. Chen, E.C. Park, N. Lu, M. Selig, G. Nielsen, T.
Taksir, R.K. Jain, B. Seed, Tumor induction of VEGF promoter activity in stromal
cells, Cell 94 (1998) 715–725.
[82] V.L. Thijssen, R.J. Brandwijk, R.P. Dings, A.W. Grifﬁoen, Angiogenesis gene ex-
pression proﬁling in xenograft models to study cellular interactions, Exp. Cell
Res. 299 (2004) 286–293.
[83] A.A. Gilad, T. Israely, H. Dafni, G. Meir, B. Cohen, M. Neeman, Functional and mo-
lecular mapping of uncoupling between vascular permeability and loss of vascu-
lar maturation in ovarian carcinoma xenografts: the role of stroma cells in
tumor angiogenesis, Int. J. Cancer 117 (2005) 202–211.
[84] K. Pietras, A. Ostman, Hallmarks of cancer: interactions with the tumor stroma,
Exp. Cell Res. 316 (2010) 1324–1331.
[85] K. Pietras, J. Pahler, G. Bergers, D. Hanahan, Functions of paracrine PDGF signal-
ing in the proangiogenic tumor stroma revealed by pharmacological targeting,
PLoS Med. 5 (2008) e19.
[86] D. Leali, P. Dell'Era, H. Stabile, B. Sennino, A.F. Chambers, A. Naldini, S. Sozzani, B.
Nico, D. Ribatti, M. Presta, Osteopontin (Eta-1) and ﬁbroblast growth factor-2
cross-talk in angiogenesis, J. Immunol. 171 (2003) 1085–1093.
[87] J. Dai, L. Peng, K. Fan, H. Wang, R. Wei, G. Ji, J. Cai, B. Lu, B. Li, D. Zhang, Y. Kang, M.
Tan, W. Qian, Y. Guo, Osteopontin induces angiogenesis through activation of
PI3K/AKT and ERK1/2 in endothelial cells, Oncogene 28 (2009) 3412–3422.
[88] G. Chakraborty, S. Jain, G.C. Kundu, Osteopontin promotes vascular endothelial
growth factor-dependent breast tumor growth and angiogenesis via autocrine
and paracrine mechanisms, Cancer Res. 68 (2008) 152–161.
[89] J. Dong, J. Grunstein, M. Tejada, F. Peale, G. Frantz, W.C. Liang, W. Bai, L. Yu, J.
Kowalski, X. Liang, G. Fuh, H.P. Gerber, N. Ferrara, VEGF-null cells require
PDGFR alpha signaling-mediated stromal ﬁbroblast recruitment for tumorigen-
esis, EMBO J. 23 (2004) 2800–2810.
[90] Y. Crawford, I. Kasman, L. Yu, C. Zhong, X.Wu, Z. Modrusan, J. Kaminker, N. Ferrara,
PDGF-C mediates the angiogenic and tumorigenic properties of ﬁbroblasts associ-
ated with tumors refractory to anti-VEGF treatment, Cancer Cell 15 (2009) 21–34.
[91] M. Augsten, C. Hagglof, E. Olsson, C. Stolz, P. Tsagozis, T. Levchenko, M.J.
Frederick, A. Borg, P. Micke, L. Egevad, A. Ostman, CXCL14 is an autocrine growth
factor for ﬁbroblasts and acts as a multi-modal stimulator of prostate tumor
growth, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3414–3419.
[92] S. Vong, R. Kalluri, The role of stromal myoﬁbroblast and extracellular matrix in
tumor angiogenesis, Genes Cancer 2 (2012) 1139–1145.
[93] R.L. Yauch, S.E. Gould, S.J. Scales, T. Tang, H. Tian, C.P. Ahn, D. Marshall, L. Fu, T.
Januario, D. Kallop, M. Nannini-Pepe, K. Kotkow, J.C. Marsters, L.L. Rubin, F.J. de
Sauvage, A paracrine requirement for hedgehog signalling in cancer, Nature
455 (2008) 406–410.
[94] K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B.
Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig,
C. Combs, S.P. Winter, H. Ireland-Zecchini, S. Reichelt, W.J. Howat, A. Chang, M.
Dhara, L. Wang, F. Ruckert, R. Grutzmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani,
P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K.
McGovern, J. Adams, C. Iacobuzio-Donahue, J. Grifﬁths, D.A. Tuveson, Inhibition of
Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pan-
creatic cancer, Science 324 (2009) 1457–1461.
[95] A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem,
V.J. Carey, A.L. Richardson, R.A. Weinberg, Stromal ﬁbroblasts present in invasive
human breast carcinomas promote tumor growth and angiogenesis through el-
evated SDF-1/CXCL12 secretion, Cell 121 (2005) 335–348.
[96] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144
(2011) 646–674.
[97] T. Silzle, M. Kreutz, M.A. Dobler, G. Brockhoff, R. Knuechel, L.A. Kunz-Schughart,
Tumor-associated ﬁbroblasts recruit blood monocytes into tumor tissue, Eur. J.
Immunol. 33 (2003) 1311–1320.
[98] B.J. Boersma, M. Reimers, M. Yi, J.A. Ludwig, B.T. Luke, R.M. Stephens, H.G.
Yfantis, D.H. Lee, J.N. Weinstein, S. Ambs, A stromal gene signature associated
with inﬂammatory breast cancer, Int. J. Cancer 122 (2008) 1324–1332.[99] B. Grum-Schwensen, J. Klingelhofer, M. Grigorian, K. Almholt, B.S. Nielsen, E.
Lukanidin, N. Ambartsumian, Lung metastasis fails in MMTV-PyMT oncomice
lacking S100A4 due to a T-cell deﬁciency in primary tumors, Cancer Res. 70
(2010) 936–947.
[100] D.G. Stover, B. Bierie, H.L. Moses, A delicate balance: TGF-beta and the tumor mi-
croenvironment, J. Cell. Biochem. 101 (2007) 851–861.
[101] M. Balsamo, F. Scordamaglia, G. Pietra, C. Manzini, C. Cantoni, M. Boitano, P.
Queirolo, W. Vermi, F. Facchetti, A. Moretta, L. Moretta, M.C. Mingari, M. Vitale,
Melanoma-associated ﬁbroblasts modulate NK cell phenotype and antitumor
cytotoxicity, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 20847–20852.
[102] M. Kraman, P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, A.
Gopinathan, D.A. Tuveson, D.T. Fearon, Suppression of antitumor immunity by
stromal cells expressing ﬁbroblast activation protein-alpha, Science 330
(2010) 827–830.
[103] D. Liao, Y. Luo, D. Markowitz, R. Xiang, R.A. Reisfeld, Cancer associated ﬁbro-
blasts promote tumor growth and metastasis by modulating the tumor immune
microenvironment in a 4T1 murine breast cancer model, PLoS One 4 (2009)
e7965.
[104] V. Assi, J. Warwick, J. Cuzick, S.W. Duffy, Clinical and epidemiological issues in
mammographic density, Nat. Rev. Clin. Oncol. 9 (2012) 33–40.
[105] G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G.
Omeroglu, S. Meterissian, A. Omeroglu, M. Hallett, M. Park, Stromal gene ex-
pression predicts clinical outcome in breast cancer, Nat. Med. 14 (2008)
518–527.
[106] A. Planche, M. Bacac, P. Provero, C. Fusco, M. Delorenzi, J.C. Stehle, I. Stamenkovic,
Identiﬁcation of prognostic molecular features in the reactive stroma of human
breast and prostate cancer, PLoS One 6 (2011) e18640.
[107] R.A. Walker, Are all ductal proliferations of the breast premalignant? J. Pathol.
195 (2001) 401–403.
[108] J.T. Camp, F. Elloumi, E. Roman-Perez, J. Rein, D.A. Stewart, J.C. Harrell, C.M.
Perou, M.A. Troester, Interactions with ﬁbroblasts are distinct in basal-like and
luminal breast cancers, Mol. Cancer Res. 9 (2011) 3–13.
[109] J.M. Fleming, T.C. Miller, M. Quinones, Z. Xiao, X. Xu, M.J. Meyer, E. Ginsburg, T.D.
Veenstra, B.K. Vonderhaar, The normal breast microenvironment of premenopausal
women differentially inﬂuences the behavior of breast cancer cells in vitro and in
vivo, BMC Med. 8 (2010) 27.
[110] M.H. Barcellos-Hoff, S.A. Ravani, Irradiated mammary gland stroma promotes
the expression of tumorigenic potential by unirradiated epithelial cells, Cancer
Res. 60 (2000) 1254–1260.
[111] K. Ohuchida, K. Mizumoto, M. Murakami, L.W. Qian, N. Sato, E. Nagai, K.
Matsumoto, T. Nakamura, M. Tanaka, Radiation to stromal ﬁbroblasts increases
invasiveness of pancreatic cancer cells through tumor-stromal interactions,
Cancer Res. 64 (2004) 3215–3222.
[112] R. Twombly, Avastin's uncertain future in breast cancer treatment, J. Natl Cancer
Inst. 103 (2011) 458–460.
[113] E. Allen, I.B. Walters, D. Hanahan, Brivanib, a dual FGF/VEGF inhibitor, is active
both ﬁrst and second line against mouse pancreatic neuroendocrine tumors de-
veloping adaptive/evasive resistance to VEGF inhibition, Clin. Cancer Res. 17
(2011) 5299–5310.
[114] B.L. Falcon, K. Pietras, J. Chou, D. Chen, B. Sennino, D. Hanahan, D.M. McDonald,
Increased vascular delivery and efﬁcacy of chemotherapy after inhibition of
platelet-derived growth factor-B, Am. J. Pathol. 178 (2011) 2920–2930.
[115] J.T. Erler, K.L. Bennewith, T.R. Cox, G. Lang, D. Bird, A. Koong, Q.T. Le, A.J. Giaccia,
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruit-
ment to form the premetastatic niche, Cancer Cell 15 (2009) 35–44.
[116] C. Gialeli, A.D. Theocharis, N.K. Karamanos, Roles of matrix metalloproteinases in
cancer progression and their pharmacological targeting, FEBS J. 278 (2011)
16–27.
[117] E.S. Radisky, D.C. Radisky, Matrixmetalloproteinase-induced epithelial-mesenchymal
transition in breast cancer, J. Mammary Gland Biol. Neoplasia 15 (2010) 201–212.
[118] Y. Kojima, A. Acar, E.N. Eaton, K.T. Mellody, C. Scheel, I. Ben-Porath, T.T. Onder, Z.C.
Wang, A.L. Richardson, R.A. Weinberg, A. Orimo, Autocrine TGF-beta and stromal
cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting
mammary stromal myoﬁbroblasts, Proc. Natl. Acad. Sci. U. S. A. 107 (2010)
20009–20014.
[119] U.M. Polanska, A. Acar, A. Orimo, Experimental generation of carcinoma-associated
ﬁbroblasts (CAFs) from human mammary ﬁbroblasts, J. Vis. Exp. (2011) e3201.
